More News

IMU and UK Biobank to generate world’s most detailed picture of the human immune system

Jim Cornall -
IMU Biosciences has announced a collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood...

Positive results from schizophrenia study

Jim Cornall -
Tortugas Neuroscience has announced positive phase 2b trial results for obuprazine (TRTL-107), the company’s investigational treatment for schizophrenia. Results from...

Jyong Biotech looks to Texas

Jim Cornall -
Jyong Biotech Ltd. says it plans to establish a potential new manufacturing facility and US operations centre in Texas. The...

New AI tool helps diagnose Ewing sarcoma

Jim Cornall -
A team from the Universitat Politècnica de València (UPV) and the University of Valencia (UV) has developed and validated...

Antibody shows attacking tumour environment also kills cancer cells

Jim Cornall -
Basque biopharmaceutical company Oncomatryx has taken part, together with German research institutions, in a study showing in patient tumour...

FDA clearance leads to influenza trial

Jim Cornall -
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) has announced that the U.S. Food and Drug Administration (FDA) has granted its...

Plasmonic coating paves way for rapid sepsis diagnosis

Jim Cornall -
A research team has developed a label-free surface-enhanced Raman scattering (SERS) analysis technology that rapidly detects extremely low concentrations...

Mentara Therapeutics launches to tackle dyskinesia

Jim Cornall -
Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, has launched with the acquisition of EM-221, now...

Base to Base biotech podcast 80: Targeting tumour acidity, and developing allosteric therapies

Jim Cornall -
This week, we chat with Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, about tumour...

IQVIA looks to help life sciences companies predict clinical trial outcomes

Jim Cornall -
IQVIA has launched IQVIA Life Science Models to help predict clinical trial outcomes. IQVIA Life Science Models are a suite...

New regulator of muscle regeneration discovered

Jim Cornall -
Skeletal muscles can regenerate following an injury, a process depending on muscle stem cells. In healthy resting muscle, these...

AI system could transform global rabies testing

Jim Cornall -
Rabies virus detection in cell cultures could soon become faster and more accessible, thanks to a world-first AI system...

Life Sciences BC announces seventh annual investor readiness programme

Jim Cornall -
Life Sciences BC (LSBC) has announced the companies selected for its 2027 Investor Readiness Program (IRP). The IRP is...

Mammals produce cyclo-octasulphur to protect cells from lipid damage

Jim Cornall -
Elemental sulphur is well known in microorganisms, plants, and fungi, but whether mammals produce and use elemental sulphur has...

New antibiotic resistance mechanism discovered in superbug Pseudomonas aeruginosa

Jim Cornall -
A joint research team led by Hongbaek Cho of the Department of Biological Sciences at Sungkyunkwan University (SKKU) and...

Preclinical data demonstrate prime-editing correction of pathogenic BRCA1 splice-site mutation

Jim Cornall -
Origin Genomics has announced initial preclinical results from OG-101, its BRCA1 gene-correction research programme. The company screened three prime-editor...

Undecimal Bio launches with $18m to address ‘liver trap’ in siRNA therapeutic delivery

Jim Cornall -
Undecimal Bio, a platform biotechnology company advancing targeted delivery of siRNA therapeutics, has announced an oversubscribed $18m seed financing. The...

Technology inspired by 3D printing could transform how medicines are tailored to patients

Jim Cornall -
Many medicines today are produced in standard doses, even though patients often have very different treatment needs. In her...

Growing optical fibres using biology

Jim Cornall -
A new project led by Northumbria University aims to grow optical fibres using proteins, mimicking a process that has...

Base to Base biotech podcast 79: Fragile X syndrome and Parkinson’s disease

Jim Cornall -
This week, we chat with Simon Mølgaard, co-founder and chief executive officer of Teitur Trophics about results from its...

Novel cancer therapy blocks communication between cancer cells and cancer-associated fibroblasts

Jim Cornall -
A research team led by Yoosoo Yang of the Department of Integrative Biotechnology at Sungkyunkwan University (SKKU), in collaboration...